Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival.
Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival.
复制标题
DOI：
10.1038/sj.bjc.6602920
复制
发表时间：
2006-01-30
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
转化生长因子-β (TGFβ)1 被认为与乳腺癌进展有关。然而，有关 TGFβ1 对乳腺癌发展影响的数据是相互矛盾的。为了阐明 TGFβ1 的临床相关性，通过酶免疫测定法测量了 193 个乳腺肿瘤样本中的 TGFβ1 蛋白水平。我们发现 94.3% 的患者表达 TGFβ1，蛋白范围为 0–684 pg mg−1。在总体人群中，与绝经后亚组相比，绝经前患者的肿瘤 TGFβ1 有所增加 (P=0.0006)。当根据淋巴结状态对患者进行细分时，在淋巴结阴性亚组中，TGFβ1 与 1 型纤溶酶原激活剂抑制剂相关（P=0.040）。多变量分析显示，继淋巴结状态（P=0.0002）和尿激酶型纤溶酶原激活剂（P=0.004）之后，TGFβ1 是总体人群中 DFS 的独立预后标志物（P=0.005）。在淋巴结阴性人群中，TGFβ1 是主要的预后因素（P=0.010）。在同一人群中，Kaplan-Meier 曲线表明，高 TGFβ1 水平与较短的无病生存期相关 (P=0.020)。这些数据表明，测量肿瘤 TGFβ1 蛋白水平，尤其是淋巴结阴性患者，可能有助于在肿瘤进展早期识别高危人群。
Transforming growth factor-beta (TGFβ)1 is thought to be implicated in breast cancer progression. However, data about the influence of TGFβ1 on breast cancer development are conflicting. To clarify the clinical relevance of TGFβ1, TGFβ1 protein level has been measured by enzyme-immoassay in 193 breast tumour samples. We found that 94.3% of patients expressed TGFβ1 with a range of 0–684 pg mg−1 protein. In the overall population, an increase of tumoral TGFβ1 was observed in premenopausal patients when compared to postmenopausal subgroup (P=0.0006). When patients were subdivided according to nodal status, TGFβ1 was correlated to type-1 plasminogen activator inhibitor in the node-negative subgroup (P=0.040). Multivariate analysis revealed that, after lymph node status (P=0.0002) and urokinase-type plasminogen activator (P=0.004), TGFβ1 was an independent prognostic marker for DFS (P=0.005) in the overall population. In the node-negative population, TGFβ1 was the prominent prognostic factor (P=0.010). In the same population, Kaplan–Meier curves demonstrated that high TGFβ1 level was correlated with a shorter disease-free survival (P=0.020). These data suggest that the measurement of tumoral TGFβ1 protein level, especially for node-negative patients, might help to identify a high-risk population early in tumour progression.
登录
查看更多内容
影响因子：
64.5
作者：
KNABBE, C;LIPPMAN, ME;DICKSON, RB
通讯作者：
DICKSON, RB
影响因子：
7.3
作者：
DUBLIN, EA;BARNES, DM;LEVISON, DA
通讯作者：
LEVISON, DA
影响因子：
8.8
作者：
MURRAY, PA;BARRETTLEE, P;COOMBES, RC
通讯作者：
COOMBES, RC
影响因子：
10.3
作者：
Look, MP;van Putten, WLJ;Foekens, JA
通讯作者：
Foekens, JA
影响因子：
2
作者：
Lebrecht, A;Grimm, C;Koelbl, H
通讯作者：
Koelbl, H